Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Insider Filings - CORMACK SCOTT DANIEL
Last Updated 
16-Jun-15
Enter symbol:
symbol lookup

 

EDGAR Online: Get a Free Trial to EDGAR Online Premium | Full text Search

CORMACK SCOTT DANIEL: Declared Holdings
Company/RelationshipReportedShares  Ownership
OncoGenex Pharmaceuticals Inc.
Officer
NasdaqCM:OGXI
(historical quotes, profile, other insiders)
12-Jun-15111,942  Direct

Insider & restricted shareholder transactions reported over the last two years
DateSharesStockTransaction
12-Jun-15 9,375OGXI Option Exercise at $0 per share.
12-Jun-15 4,571OGXI Sale at $2.69 per share.
(Proceeds of $12,295)
20-May-15 7,543OGXI Sale at $1.88 per share.
(Proceeds of $14,180)
19-May-15 15,624OGXI Option Exercise at $0 per share.
30-Jan-15 9,206OGXI Disposition (Non Open Market) at $2.11 per share.
(Value of $19,424)
27-Jan-15 20,100OGXI Option Exercise at $0 per share.
19-Sep-14 3,401OGXI Disposition (Non Open Market) at $3.06 per share.
(Value of $10,407)
17-Sep-14 7,425OGXI Option Exercise at $0 per share.
13-Aug-14 18,341OGXI Sale at $3.17 per share.
(Proceeds of $58,140)
12-Aug-14 37,500OGXI Option Exercise at $0 per share.
17-Mar-14 4,634OGXI Sale at $12.25 per share.
(Proceeds of $56,766)
14-Mar-14 9,376OGXI Option Exercise at $0 per share.
13-Aug-13 2,951OGXI Disposition (Non Open Market) at $0 per share.
13-Aug-13 6,562OGXI Option Exercise at $0 per share.


EDGAR Online: Get a Free Trial to EDGAR Online Premium | Full text Search


Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Data and information are provided by EDGAR Online, Inc. for informational purposes only and not intended for trading purposes. Yahoo!, EDGAR Online, Inc. shall have no liability for the accuracy of the information furnished or for delays, omissions or opinions expressed therein. You may not use the information for any illegal purpose or furnish the information to any person, firm, or branch office for commercial re-use or re-sale.

Questions or Comments?